- Home
- ABAT vs NMRA Comparison
ABAT vs NMRA Comparison
Compare ABAT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- NMRA
- Stock Information
- Founded
- ABAT 2011
- NMRA 2019
- Country
- ABAT United States
- NMRA United States
- Employees
- ABAT N/A
- NMRA N/A
- Industry
- ABAT Metal Mining
- NMRA
- Sector
- ABAT Basic Materials
- NMRA
- Exchange
- ABAT Nasdaq
- NMRA Nasdaq
- Market Cap
- ABAT 232.2M
- NMRA 268.5M
- IPO Year
- ABAT N/A
- NMRA 2023
- Fundamental
- Price
- ABAT $2.49
- NMRA $1.50
- Analyst Decision
- ABAT
- NMRA Hold
- Analyst Count
- ABAT 0
- NMRA 8
- Target Price
- ABAT N/A
- NMRA $5.83
- AVG Volume (30 Days)
- ABAT 3.4M
- NMRA 372.9K
- Earning Date
- ABAT 11-14-2025
- NMRA 11-11-2025
- Dividend Yield
- ABAT N/A
- NMRA N/A
- EPS Growth
- ABAT N/A
- NMRA N/A
- EPS
- ABAT N/A
- NMRA N/A
- Revenue
- ABAT $1,857,877.00
- NMRA N/A
- Revenue This Year
- ABAT $718.34
- NMRA N/A
- Revenue Next Year
- ABAT $1,505.37
- NMRA N/A
- P/E Ratio
- ABAT N/A
- NMRA N/A
- Revenue Growth
- ABAT N/A
- NMRA N/A
- 52 Week Low
- ABAT $0.73
- NMRA $0.61
- 52 Week High
- ABAT $4.11
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- ABAT 52.87
- NMRA 49.58
- Support Level
- ABAT $2.26
- NMRA N/A
- Resistance Level
- ABAT $2.77
- NMRA $1.70
- Average True Range (ATR)
- ABAT 0.18
- NMRA 0.08
- MACD
- ABAT -0.02
- NMRA -0.08
- Stochastic Oscillator
- ABAT 47.37
- NMRA 81.74
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.